https://www.selleckchem.com/pr....oducts/edralbrutinib
54 ± 0.58ng/mg and that of controls was 7.99 ± 1.16 ng/ mg. Persons on dupilumab reported a statistically increased occurrence of ocular fatigue/eye strain, uncomfortable sensation, pain, red eye, and itching. This study demonstrates for the first time, a relative deficiency of Muc5AC in patients on dupilumab. The results of this study support the previously reported role of IL-13 in increasing goblet cell density and associated Muc5AC production. Further efforts are underway to better understand the relative contribution of Muc5A
Like
Comment
Share
